Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Matthews PC, Barrett LK, Warren S et al (2016) Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. BMC Infect Dis 16(1):556
2. Hashemian SMR, Farhadi Z, Farhadi T (2019) Fosfomycin: the characteristics, activity, and use in critical care. Ther Clin Risk Manag 27(15):525–530
3. Cao Y, Peng Q, Li S et al (2019) The intriguing biology and chemistry of fosfomycin: the only marketed phosphonate antibiotic. RSC Adv 9(72):42204–42218
4. Anastasia A, Bonura S, Rubino R et al (2023) The use of intravenous fosfomycin in clinical practice: a 5-year retrospective study in a tertiary hospital in Italy. Antibiotics (Basel) 12(6):971
5. Ruiz Ramos J, Salavert Lletí M (2019) Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens. Rev Esp Quimioter 32(Suppl 1):45–54